New and known type 2 diabetes as coronary heart disease equivalent: results from 7.6 year follow up in a middle east population by Hadaegh, Farzad et al.
ORIGINAL INVESTIGATION Open Access
New and known type 2 diabetes as coronary
heart disease equivalent: results from 7.6 year
follow up in a middle east population
Farzad Hadaegh
1*, Nooshin Fahimfar
1, Davood Khalili
1,2, Farhad Sheikholeslami
1, Fereidoun Azizi
3
Abstract
Background: To investigate whether the known diabetes mellitus (KDM) or newly diagnosed diabetes mellitus
(NDM) could be regarded as a coronary heart disease (CHD) risk equivalent among a relatively young Middle East
population with high prevalence of diabetes mellitus (DM).
Methods: A population based cohort study of 2267 men and 2931 women, aged ≥ 30 years. Prior CHD was
defined as self-reported or ECG positive CHD at baseline, KDM as subjects using any kind of glucose-lowering
medications and NDM according to fasting plasma glucose and 2-h postchallenge glycemia.
Participants were categorized to six groups according to the presence of known or newly diagnosed DM and CHD
at baseline (DM-/CHD-, DM-/CHD+, NDM+/CHD-, NDM+/CHD+, KDM+/CHD-, KDM+/CHD+) and Cox regression
analysis were used to estimate the hazard ratio (HR) of CHD events for these DM/CHD groups, given DM-/CHD-as
the reference.
Results: During 7.6-year follow up, 358 CHD events occurred. After controlling traditional risk factors, HRs of CHD
events for DM-/CHD+ group were 2.1 (95% CI: 1.4-3.1) and 5.2 (3.2-8.3) in men and women respectively.
Corresponding HRs for NDM+/CHD-were 1.7 (1.1-2.7) and 3.1 (1.8-5.6) and for KDM+/CHD-were 1.7 (0.9-3.3) and 6.2
(3.6-10.6) in men and women respectively. The HRs for NDM+/CHD+ and KDM+/CHD+ groups (i.e. participants
with history of both diabetes and CHD) were 6.4 (3.2-12.9) and 8.0 (4.3-14.8) in women and 3.2 (1.9-5.6) and 4.2
(2.2-7.8) in men, respectively.
The hazard of CHD events did not differ between KDM+/CHD-and DM-/CHD+ in both genders using paired
homogeneity test, however the HR for NDM+/CHD-was marginally lower than the HR for DM-/CHD+ in women
(p = 0.085).
Conclusions: KDM patients in both genders and NDM especially in men exhibited a CHD risk comparable to
nondiabetics with a prior CHD, furthermore diabetic subjects with prior CHD had the worst prognosis, by far more
harmful in women than men; reinforcing the urgent need for intensive care and prophylactic treatment for
cardiovascular diseases.
Background
The most important cause of mortality in diabetic
patients is cardiovascular disease (CVD) [1] and obser-
vational studies have shown that diabetes mellitus (DM)
increases risk of CVD nearly two to three folds [1,2]. In
addition, some cohort studies conducted in American
and European populations have suggested that rates for
coronary heart disease (CHD) events are equivalent to
both individuals with prior CHD and diabetic subjects
without prior CHD [1-4]. Therefore, the American Dia-
betes Association recommended that, in secondary pre-
vention, the diabetic patients should be treated for the
same lipid and blood pressure targets as subjects with
previous myocardial infarction [5]. Some other studies
have found that cardiovascular risk are lower in subjects
with diabetes but without CHD, than in persons with
CHD and without diabetes [6-8]; however a few studies
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it is not clear whether these findings can be generalized
to other populations because relative mortality risks may
differ with ethnicity [9-11].
It is estimated that developing countries in Asia and
in the Middle East, particularly in Persian Gulf states,
will have the largest increases in the prevalence of dia-
betes by 2030, which is related to major shift in life
style and nutrition transition in these countries [12-17].
Nevertheless, to our best knowledge, there is no study
to show the equivalency of diabetes and prior CHD for
risk of CHD in this region.
T h ep r e v a l e n c eo fT y p e2d i a b e t e si sr e p o r t e dt ob e
more than 14% in Tehran, Iran, with an estimated inci-
dence of new cases in about 1% of the population per
year [14,15]. There is a high prevalence of CHD in this
area too [18] and it has been shown that the Iranian
population with diabetes has a high risk for CVD, inde-
pendent of traditional risk factors [19]. Hence, we com-
pared the risk of CHD events among diabetic
participants without prior CHD to that of participants
diagnosed as having CHD but not diabetes in the frame-
work of the Tehran Lipid and Glucose Study (TLGS)
which is a population based study conducted on a repre-
sentative population of the capital city, Tehran [20].
Furthermore, we analyzed the results separately for
newly diagnosed DM and known DM, and in addition
t oap r i o rh i s t o r yo fC H D ,w ea p p l i e de l e c t r o c a r d i o -
graphic criteria for the presence of CHD at baseline.
Methods
Study population
The TLGS is a prospective population-based study to
determine the risk factors for non-communicable dis-
eases among a representative urban population of Teh-
ran [20]. The sampling method has been described
elsewhere [20]. Briefly, a total of 15005 individuals
aged 3 years and over who were residences of district
No.13 of Tehran were selected using multistage cluster
random sampling method. Subjects were categorized
into the cohort and intervention groups, the latter to
be educated for implementation of life style changes
[20]. From among 8071 individuals, aged ≥ 30 years,
who participated in the first phase of TLGS (February
1999 to August 2001), 5981 subjects had complete data
of electrocardiogram (ECG) and history of CHD.
Excluding participants with other missing data (n =
155) resulted in 5826 subjects at baseline; of those we
followed 5198 (64.4% of total) until 20 March 2008
with a median follow up of 7.6 years (Figure 1). Written
informed consent was obtained from all subjects and
the ethical committee of Research Institute for Endo-
crine Sciences approved this study.
Clinical and laboratory measurements at enrolment
The information was collected during a personal inter-
view, and completion of a questionnaire for demo-
graphic factors, medical history, medication use and
smoking. Physical examination for blood pressure and
anthropometrical measurements was performed. Blood
pressure was measured twice in a seated position after
15 min resting using a standard mercury sphygmoman-
ometer and the mean of the two measurements was
considered as the subject’s blood pressure. Body mass
index (BMI) was calculated as weight (kg) divided by
the square of height (m
2).
Two trained technicians recorded a 12-lead ECG
according to the standard recording protocol developed
by the School of Public Health, the University of Minne-
sota using a PC-ECG 1200 machine [21]. Two qualified
physicians coded the ECGs in parallel according to the
Minnesota codes using a measuring loupe specially man-
ufactured by University of Minnesota [21]. Then, for
a s s u r a n c eo fq u a l i t yat h i r dq u alified physician recoded
10% of ECGs. All the data were double-checked.
Fasting plasma glucose (FPG) and lipid profiles were
tested after 12-14 hours overnight fasting. Standard oral
glucose tolerance test (OGTT) was performed in partici-
pants without treated diabetes. All analyses were done
at the TLGS research laboratory on the day of collec-
tion. Plasma glucose, serum total cholesterol, high-
density lipoprotein cholesterol (HDL-C) and triglyceride
(TG) levels were measured by using previously reported
methods [20].
8071 
≥30 years old at the baseline 
5981 
With ECG and History of CHD 
5826 
Complete data  
155 
Excluded due to lack of 
information 
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Under follow up 
(2267 men and 2931 women) 
628 
Excluded because of no 
follow up 
2090 
Excluded because of 
incomplete data of ECG or 
history of coronary heart 
disease (CHD) 
Figure 1 Study participants’ entry.
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Family history of premature CVD reflected prior diagno-
sis of CVD in female first-degree relatives, aged less
than 65 years or male first-degree relatives under the
age of 55 years old.
Smoking was defined as history of current smoking
(including daily or occasional). Newly diagnosed DM
( N D M )w a sd e f i n e da si n d i v i d u a l sw i t hF P G≥ 7.0
mmol/L (126 mg/dl) or 2-h postchallenge glycemia
(2hPG) ≥ 11.1 mmol/L (200 mg/dl) without any history
of glucose-lowering medications and Known DM
(KDM) was defined as subjects who have been treated
with any kind of glucose-lowering medications.
Prevalent CHD at enrolment
Prevalent (or prior) CHD was defined as self-reported
CHD or ECG positive CHD. Self-reported CHD was
defined as a positive answer to the question as to
“whether the subject has ever had a prior diagnosis of
CHD by a physician”. Electrocardiogram positive CHD
was defined according to the Whitehall criteria [22]
which categorize subjects into three groups, non CHD,
probable CHD (any Minnesota codes of 1.1.1 through
1.1.7and 1.2.1 through 1.2.8) and possible CHD (codes
of 1.3.1 through 1.3.6, 4.1.1 through 4.4, 5.1 through 5.3
or 7.1.1 through 7.1.2). In our analysis, we considered
both probable and possible CHD as a single definition
of ECG-positive CHD.
We divided our cohort into six groups based on their
clinical status at the baseline examination:
- Subjects without newly diagnosed or known DM and
without prior CHD (DM-/CHD-)
- Subjects without newly diagnosed or known DM but
with prior CHD (DM-/CHD+)
- Subjects with NDM but without prior CHD (NDM
+/CHD-)
- Subjects with NDM and with prior CHD (NDM
+/CHD+)
- Subjects with KDM but without prior CHD (KDM
+/CHD-)
- Subjects with KDM and with prior CHD (KDM
+/CHD+)
Definition of CHD outcome
Each TLGS participant is under continuous surveillance
for any medical event leading to hospitalization during
the previous year by telephone call and he/she is ques-
tioned by a trained nurse regarding any medical condi-
tions. If a related event has occurred, a trained physician
collects complementary data during a home visit, and
when deemed necessary, a visit to the respective hospital
for collecting data from the participant’s medical files
was done. In the case of mortality, data are collected
from the hospital or death certificate by an authenticated
local physician. Collected data are evaluated by an out-
come committee consisting of a principal investigator, an
internist, an endocrinologist, a cardiologist, an epidemiol-
ogist and the physician who collected the outcome data;
other experts are invited for evaluation of non-commu-
nicable disorders as needed. Specific outcome for every
event is assigned according to ICD-10 criteria and Amer-
ican Heart Association classification for cardiovascular
events [20].
In the current study, CHD events as outcomes
included cases of definite myocardial infarction (MI)
diagnosed by electrocardiogram (ECG) and biomarkers,
probable MI (positive ECG findings plus cardiac symp-
toms or signs but biomarkers showing negative or equi-
vocal results), unstable angina pectoris (new cardiac
symptoms or changing symptom patterns and positive
ECG findings with normal biomarkers), angiographic
proven CHD and CHD death.
Statistics
The results for continues variables are given as mean
(± SD) and for categorical variables as percentages.
Comparisons of the baseline characteristics among DM/
C H Dg r o u p sw e r ed o n eu s i n gA N O V Ao rc2t e s ta n d
we used t-test or c2 test to compare any group with the
DM-/CHD+ group considering Bonferroni correction
for multiple comparisons.
Cox proportional hazard regression models were used
to estimate the hazard ratio (HR) of CHD events for
DM/CHD groups (DM-/CHD+, NDM+/CHD-, NDM
+/CHD+, KDM+/CHD-, KDM+/CHD+) in both gen-
ders, given DM-/CHD-as the reference group. Follow up
duration was defined as the period between the entrance
to study and the end point; end point was considered as
the first CHD event and participants were censored at
non-CHD death or end of follow-up. Analyses were
done with adjustment for age alone and for age with
other possible risk factors including systolic blood pres-
sure, body mass index (BMI), total cholesterol, TG/
HDL-C [23], family history of premature CVD, smoking
and being in the intervention group. The proportional
hazards assumption in the Cox model was assessed
using log minus log plot of survival and Schoenfeld resi-
dual test. All proportional hazards assumptions were
generally appropriate (p-value for global test of propor-
tional hazards assumption was > 0.1 in men and
women).
A paired homogeneity test, which is a Wald test of the
linear hypothesis of the Cox model regression coeffi-
cients, was performed to test the null hypothesis that
the hazard ratio for NDM+/CHD-and KDM+/CHD-was
equal to that for DM-/CHD+.
Statistical analyses were performed using SPSS for
windows version 15 and STATA version 10, and
Hadaegh et al. Cardiovascular Diabetology 2010, 9:84
http://www.cardiab.com/content/9/1/84
Page 3 of 8p-values less than 0.05 were considered statistically sig-
nificant. All analyses were separated by gender regarding
significant interaction between gender and some of the
DM/CHD categories to predict CVD events.
Results
In comparison to men who were not included in the
study, those who were had less history of smoking (27%
vs. 31.5%). Women included were younger (46.9 vs. 47.8
years), had lower systolic blood pressure (122 vs. 124
mmHg) and higher BMI (28.6 vs. 28.1 kg/m2) than
those not included (all p < 0.05).
Baseline characteristics for all groups are shown in
Table 1 and 2. Compared to the DM-/CHD+ group,
NDM+/CHD-had higher TG/HDL-C and BMI values in
men and higher TG/HDL-C, BMI and systolic blood
pressure values in women; also KDM+/CHD-had higher
systolic blood pressure and TG/HDL-C in women.
Overall, 212 (9.4%) men and 146 (5%) women had
CHD events during 16033 and 21433 person-years of
follow up; the corresponding incidence density of CHD
event were 13.2 and 6.8 per 1000 person-years in men
and women respectively. In men, 46 (20.2%) of DM-/
CHD+, 26 (17.1%) of NDM+/CHD-and 11(15.9%) of
KDM+/CHD-individuals experienced CHD events; these
values in women were 39 (13.7%), 19 (9.0%) and 25
(18.1%) respectively.
Table 3 and 4 and Figure 2 highlight the HR of coron-
ary heart disease in relation with DM and prior CHD in
men and women. Age adjusted analysis revealed notably
higher risks in DM-/CHD+, NDM+/CHD-and KDM
+/CHD-groups compared with DM-/CHD-in both gen-
ders. However, in multivariate analysis, DM-/CHD+ and
NDM+/CHD-in both genders and KDM+/CHD-only in
women remained as significant predictors of CHD
events. The risks of patients with DM or CHD were
higher in women than men (in all of the DM/CHD cate-
gories) and p-value for the effect modification by gender
reached the significant level of 0.05 in DM-/CHD+ and
KDM+/CHD-groups (p = 0.002 for both). Hazard ratios
of CHD events were 2.1 (95%CI: 1.4-3.1), 1.7 (1.1-2.7)
and 1.7 (0.9-3.3) for DM-/CHD+, NDM+/CHD-and
KDM+/CHD-respectively in men, values which were 5.2
(3.2-8.3), 3.1 (1.8-5.6) and 6.2 (3.6-10.6) in women.
Considering both NDM and KDM in a DM+/CHD-
group, the HR of this group was 1.73 (95%CI: 1.15-2.60)
and 4.37 (2.74-6.97) compared to DM-/CHD-group in
men and women, respectively.
Individuals with known or newly diagnosed DM and
prior CHD demonstrated additive risks, i.e. HRs of 3.2
(95% CI: 1.9-5.6) and 4.2 (2.2-7.8) in men and 6.4 (3.2-
12.9) and 8.0 (4.3-14.8) in women for NDM+/CHD+
and KDM+/CHD+ respectively.
Finally, as shown in Table 3 and 4, the results of the
Wald test, used to compare the hazard ratios, high-
l i g h t e dt h a tt h er i s ko fC H De v e n t sd i dn o td i f f e r
between KDM+/CHD-and DM-/CHD+ in both genders,
however the risk of NDM+/CHD-was marginally lower
than the HR of DM-/CHD+ in women (p = 0.085).
Discussion
When history of CHD or ischemic ECG changes was
used to define prior CHD, this study showed that Type
2 diabetes is a “CHD equivalent” in a 7.6-year follow-up
of Iranian subjects. The risk of CHD associated with
diabetes was relatively equal to that associated with
Table 1 General characteristics of men according to DM and prior CHD status at baseline
a
DM/CHD group
Variable
b DM-/CHD- DM-/CHD+ NDM+/CHD- NDM+/CHD+ KDM+/CHD- KDM+/CHD+
number 1726 228 152 52 69 40
Age (years) 46.1 (12.1)* 56.9(12.2) 55.7(11.6) 60.8(11.6) 59.5(9.2) 63.3(8.1)*
SBP (mm Hg) 119.3 (17.0)* 131.8(23.0) 132.1(20.5) 144.1(32.0)* 132.4(20.4) 139.9(27.6)
DBP (mm Hg) 78.0 (10.7)* 80.8(12.8) 82.0(12.5) 84.3(15.7) 80.5(10.3) 81.65(13.3)
TC (mmol/L) 5.39 (1.07)* 5.78(1.16) 5.86(1.21) 5.83(1.08) 5.60(1.26) 5.61(1.07)
TG/HDL-C 5.3(4.5)* 6.1(4.6) 7.2(4.6)* 7.5(7.0) 7.5(6.9) 4.8(3.2)
BMI (kg/m²) 25.9 (3.8)* 27.0(3.7) 28.0(3.9)* 27.6(3.7) 27.6(4.0) 26.1(3.4)
Smoking (%) 29.0 21.1 20.4 32.7 20.3 17.5
FH of CVD (%) 14.8 18.4 13.2 13.5 11.6 12.5
Intervention (%) 38.0 36.8 38.2 40.4 58.0* 32.5
a Data have been shown as mean (± sd) or percent.
b In all variables except “FH of CVD” difference among categories is significant (P < 0.05 according to ANOVA or c2 test.)
*Difference with “Any DM-/CHD+” group is significant at the level of P < 0.01 (according to t-test or c2 test and considering Bonferroni correction for multiple
comparisons.).
DM: diabetes mellitus, CHD: coronary heart disease, NDM: newly diagnosed DM, KDM: known DM, SBP: systolic blood pressure, DBP: diastolic blood pressure, TC:
total cholesterol, TG/HDL-C: triglyceride/HDL cholesterol, BMI: body mass index, FH of CVD: family history of premature cardiovascular disease, Intervention: being
in intervention group.
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risk of CHD in men and women, respectively. Our find-
ings are consistent with the highly cited Haffner et al’
paper, in which Finnish known Type 2 diabetic patients
without prior myocardial infarction have as high a risk
of myocardial infarction as nondiabetic patients with
prior myocardial infarction [24]. Because the Haffner et
al. study included only 69 DM-/CHD+ individuals, the
power of the study to detect differences between the 2
groups was limited. Similarly, in a population based
study in Denmark, diabetic patients requiring glucose-
lowering agents exhibited a cardiovascular risk compar-
able to nondiabetic with a prior myocardial infarction,
regardless of sex and diabetes type [25]. However, Our
findings are in contrast with those of Lee et al, in their
Atherosclerosis Risk in Communities study (ARIC), in
which after adjustment for multiple baseline risk factors,
patients who had a history of myocardial infarction
without diabetes at baseline had a 1.9 times the risk of
fatal CHD or nonfatal myocardial infarction, compared
with diabetic patients without a prior history of myocar-
dial infarction [26]. Furthermore, in the Nurses’ Health
Study [27] and Health professional Follow-up study [8],
Type 2 diabetic patients without myocardial infarction
had a lower risk of CHD compared with myocardial
infarction patients without diabetes. Recently, data from
the REACH registry do not fully support the concept
that diabetes is a cardiovascular risk equivalent, and the
rate of pooled CVD mortality and nonfatal myocardial
infarction in nondiabetic subjects with previous CAD
was more than 50% higher than that seen in diabetic
patients with risk factors only [28]. It is important to
note that, the studies addressing these issues have great
differences in age distribution, designs, and definitions
of the study populations that could explain the discre-
pancies with our findings.
Recently we found that diabetes, in particular the
known cases, had higher risk more so in women than in
Table 2 General characteristics of women according to DM and prior CHD status at baseline
a
DM/CHD group
Variable
b DM-/CHD- DM-CHD+ NDM+/CHD- NDM+/CHD+ KDM+/CHD- KDM+/CHD+
number 2184 285 210 56 138 58
Age (years) 44.6(10.7)* 53.0(11.7) 51.2(10.0) 57.2(8.3)* 55.4(9.6) 60.6(7.8)*
SBP (mm Hg) 118.1(17.6)* 129.3(22.9) 133.9(21.6)* 139.2(22.5)* 135.8(23.0)* 140.0(23.3)*
DBP (mm Hg) 78.1(10.0)* 82.4(12.5) 84.5(11.8) 85.6(9.7) 82.6(10.5) 81.5(12.2)
TC (mmol/L) 5.61 (1.15)* 6.14(1.26) 6.24(1.25) 6.53(1.57) 6.34(1.32) 6.87(1.33)*
TG/HDL-C 4.1(3.4)* 4.9(3.9) 6.8(5.4)* 5.8(3.8) 5.9(4.4)* 6.4(4.4)*
BMI (kg/m²) 28.2(4.6)* 29.3(4.8) 30.6(4.9)* 30.1(5.0) 29.2(4.8) 29.4(5.2)
Smoking (%) 3.9 3.9 3.8 0.0 2.2 3.4
FH of CVD (%) 17.5 22.1 26.2 16.1 23.2 25.9
Intervention (%) 39.1 34.7 41.4 41.1 37.0 46.6
a Data have been shown as mean (± sd) or percent.
b In all variables except smoking and intervention difference among categories is significant (P < 0.05 according to ANOVA or c2 test.)
*Difference with “Any DM-/CHD+” group is significant at the level of P < 0.01 (according to t-test or c2 test and considering Bonferroni correction for multiple
comparisons.).
DM: diabetes mellitus, CHD: coronary heart disease, NDM: newly diagnosed DM, KDM: known DM, SBP: systolic blood pressure, DBP: diastolic blood pressure, TC:
total cholesterol, TG/HDL-C: triglyceride/HDL cholesterol, BMI: body mass index, FH of CVD: family history of premature cardiovascular disease, Intervention: being
in intervention group.
Table 3 Hazard ratio of CHD event in men according to baseline DM and prior CHD status
CHD event NO. (rate)
a Age adjusted HR p-value Multivariate
b adjusted HR p-value
DM-/CHD- 98 (7.8) Ref Ref
DM-/CHD+ 46 (30.5) 2.8(1.9-4.0) < 0.001 2.1(1.4-3.1) < 0.001
NDM+/CHD- 26 (25.5) 2.4(1.5-3.7) < 0.001 1.7(1.1-2.7)* 0.020
NDM+/CHD+ 19 (63.3) 5.3(3.2-8.9) < 0.001 3.2(1.9-5.6) < 0.001
KDM+/CHD- 11 (24.7) 2.2(1.1-4.1) 0.017 1.7(0.9-3.3)† 0.108
KDM+/CHD+ 12 (55.5) 4.7(2.5-8.7) < 0.001 4.2(2.2-7.8) < 0.001
a Incidence rate: number of cases per 1000 person-year.
b Analyses were adjusted for age, systolic blood pressure, body mass index, cholesterol, triglyceride/HDL-cholesterol, family history of cardiovascular disease,
smoking and intervention.
* The p-value to compare with the HR of DM-/CHD+ was 0.414, applying Wald test.
† The p-value to compare with the HR of DM-/CHD+ was 0.527, applying Wald test.
DM: diabetes mellitus, CHD: coronary heart disease, NDM: newly diagnosed DM, KDM: known DM, HR: hazard ratio.
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ing to the diabetes status i.e. new vs. known cases, in
women both the KDM+/CHD-and NDM+/CHD-groups
had significant risk for incident CHD in comparison
with the DM-/CHD-group (Risk factor adjusted HR ≈ 6
and ≈ 3 respectively, p < 0.001); however, in men only
NDM+/CHD-, resulted in a significant risk, in compari-
son with DM-/CHD-(HR: 1.7, 95% CI: 1.07-2.69). The
lack of association of KDM+/CHD-with incident CHD
in men might be attributed to the limited statistical
power.
As acknowledged by Gonzalez-Clemente et al, it
would probably have been better to directly compare
persons who were DM+/CHD-with those who were
DM-/CHD+ [29], hence comparing directly the hazard
ratios of the these groups using the paired homogeneity
test highlighted no difference between the KDM
+/CHD-and DM-/CHD+ groups in risk factor adjusted
analysis in prediction of incident CHD. However, an
important finding of the current study was that regard-
ing NDM in women, the risk of incident CHD in multi-
variate analysis for participants with DM -/CHD+ was
marginally higher than those with NDM+/CHD-,
although this did not reach a significant level. Consis-
tent with our findings, a similar impact of diabetes in
those receiving glucose-lowering agents (i.e. KDM) vs.
those with prior CHD in prediction of incident CHD
was demonstrated in the Multiple Risk Factor Interven-
tion Trial (MRFIT) of men, 35 to 57 years old [30].
Similarly, Carnethon et al in a longitudinal study of
men and women aged ≥ 65 years highlighted that, CHD
mortality risk was similar between participants with
CHD alone vs. diabetes alone [31]. Recently Andrersson
el, in a multivariate regression analyses showed that
patients with diabetes and absence of significant coron-
ary artery disease at angiography have impaired systolic
longitudinal left ventricular function and a global dia-
stolic dysfunction, which is likely to be associated with
adverse prognosis [32].
In the present study, diabetic subjects with prior CHD
had the worst prognosis, by far more harmful in women
than men (multivariate adjusted HR 7.19 vs. 3.58,
respectively) similar to the reports of other studies
[2,27,29] highlighting the importance of secondary pre-
vention in patients with both coexisting disorders, espe-
cially in women. Our data concerning higher risk of
CVD in women than men with DM +/CHD+ is compar-
able with female sex predominance in acute coronary
syndrome patients with diabetes from a hospital based
study from Iran [33].
Table 4 Hazard ratio of CHD event in women according to baseline DM and prior CHD status
CHD event NO. (rate)
a Age adjusted HR p-value Multivariate
b adjusted HR p-value
DM-/CHD- 35 (2.1) Ref Ref
DM-/CHD+ 39 (19.6) 6.0(3.7-9.6) < 0.001 5.2(3.2-8.3) < 0.001
NDM+/CHD- 19 (12.8) 4.4(2.5-7.7) < 0.001 3.1(1.8-5.6)* < 0.001
NDM+/CHD+ 11 (30.4) 8.2(4.1-16.4) < 0.001 6.4(3.2-12.9) < 0.001
KDM+/CHD- 25 (26.5) 7.4(4.4-12.6) < 0.001 6.2(3.6-10.6)† < 0.001
KDM+/CHD+ 17 (48.2) 11.3(6.1-20.8) < 0.001 8.0(4.3-14.8) < 0.001
a Incidence rate: number of cases per 1000 person-year.
b Analyses were adjusted for age, systolic blood pressure, body mass index, cholesterol, triglyceride/HDL-cholesterol, family history of cardiovascular disease,
smoking and intervention.
* The p-value to compare with the HR of DM-/CHD+ was 0.085, applying Wald test.
† The p-value to compare with the HR of DM-/CHD+ was 0.475, applying Wald test.
DM: diabetes mellitus, CHD: coronary heart disease, NDM: newly diagnosed DM, KDM: known DM, HR: hazard ratio.
Figure 2 Hazard ratio of CHD event according to baseline DM
and prior CHD status. Legend: DM: diabetes mellitus, CHD:
coronary heart disease, NDM: newly diagnosed DM, KDM:
known DM.
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Page 6 of 8Our study has several strengths. This is the first popu-
lation-based study in Caucasians of Middle East region,
conducted to determine the equivalency of diabetes and
prior CHD for risk of CHD event. We included newly
diagnosed DM in our study based on the OGTT result;
furthermore, the ischemic change of ECG was added for
defining prevalent CHD. However, most of the studies
on this issue, included diagnosis of CHD and diabetes
b a s e do nd a t ap r o v i d e db yt h ep a t i e n t st h e m s e l v e s ,
which may have led to misclassification of subjects in
the various groups. Finally, our study also adjusted for
major CVD risk factors in the statistical model.
Limitations of the study
This study has important limitations that should be con-
sidered. First, we used positive history of CHD and the
ECG-defined CHD as criteria to define prevalent CHD
at baseline. The principal difference between these cri-
teria might be caused by over reporting, non-Q-wave
myocardial infarctions, or the interventions implemen-
ted to alleviate blockage of the coronary arteries [22];
unfortunately, at baseline the questionnaire of TLGS did
not include questions about use of thrombolytic therapy,
coronary artery bypass surgery, or percutaneous trans-
luminal coronary angioplasty. Furthermore, population-
based studies have found self-reported MI, CHD and
stroke to be moderately or highly accurate in determin-
ing disease status [34]. Second, we defined newly diag-
nosed DM with a single OGTT at baseline as suggested
for epidemiological studies; however, this might lead to
attenuation of the association between newly diagnosed
DM and cardiovascular events, resulting in an underesti-
mation of the risk in this group. Third, the duration of
diabetes could be a factor that explains the conflicting
results in studies aiming to determine diabetes as a
CHD risk equivalent, since longer duration of diabetes
is associated with an increased risk of CVD [29].
Recently, Dagenais et al in the Quebec Cardiovascular
Study emphasized finding that compared to men with
incident CVD, men with incident diabetes had a lower
risk for CVD mortality during the first 5 years after the
diagnosis of diabetes, but subsequently there was no dif-
ference between the 2 groups for cardiovascular and
total mortality [35]. Finally, our population was selected
from middle-aged Middle East Caucasians and therefore
we cannot make inferences beyond a similar group.
Conclusions
The current study highlighted the finding that known
diabetic patients in both genders and newly diagnosed
diabetes especially in men, exhibited a CHD risk com-
parable to nondiabetics with a prior CHD, regardless of
risk factors, furthermore diabetic subjects with prior
CHD had the worst prognosis, by far more harmful in
women than men; reinforcing thus the urgent need for
intensive care and prophylactic treatment for cardiovas-
cular diseases.
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